Begré, Lorin; Boyd, Anders; Salazar-Vizcaya, Luisa; Suter, Franziska; Béguelin, Charles; Rockstroh, Jürgen K; Günthard, Huldrych F; Calmy, Alexandra; Cavassini, Matthias; Stöckle, Marcel; Schmid, Patrick; Bernasconi, Enos; Levrero, Massimo; Zoulim, Fabien; Wandeler, Gilles; Rauch, Andri (2024). Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapy. HIV medicine, 25(2), pp. 291-298. Wiley 10.1111/hiv.13561
Full text not available from this repository. (Request a copy)OBJECTIVES
Improving the understanding of the patterns of quantitative hepatitis B surface antigen (qHBsAg) trajectories associated with HBsAg loss is important in light of novel anti-hepatitis B virus agents being developed. We evaluated long-term qHBsAg trajectories in persons with HIV and HBV during tenofovir-containing antiretroviral therapy in the Swiss HIV Cohort Study.
METHODS
We included 29 participants with and 29 without HBsAg loss, defined as qHBsAg <0.05 IU/mL. We assessed qHBsAg decline during therapy in both groups and used agglomerative hierarchical clustering to identify different qHBsAg trajectory profiles in persons with HBsAg loss.
RESULTS
The median follow-up time was 11.9 years (IQR 8.4-14.1), and the median time to HBsAg loss was 48 months (IQR 12-96). Among participants with HBsAg loss, 79% had a qHBsAg decline ≥1 log10 IU/mL 2 years after starting tenofovir. The trajectories in qHBsAg levels during tenofovir therapy were heterogeneous, characterized by five distinct profiles. Among participants without HBsAg loss, only 7% had a qHBsAg decline ≥1 log10 IU/ml after 2 years.
CONCLUSIONS
Most persons with HIV who experienced HBsAg loss had an early decline in qHBsAg levels, with diverse trajectories during long-term tenofovir therapy. In persons without HBsAg loss, qHBsAg levels remained remarkably stable over time.
Actions (login required)
 |
Edit item |